Celcuity Inc.
CELC · Nasdaq · United States
Share price · CELC
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when CELC's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 22 Oct 2026+6.5%
Nothing announced by CELC that day or the session before.
- 14 Oct 2026-5.2%
Nothing announced by CELC that day or the session before.
- 7 Oct 2026-7.7%
Nothing announced by CELC that day or the session before.
- 15 Jul 2026-17.6%
- 2 Jun 2026-25.7%
- 14 May 2026+8.2%
- 4 May 2026+15.4%
- 24 Apr 2026+6.6%
Nothing announced by CELC that day or the session before.
- 23 Apr 2026-7.2%
Nothing announced by CELC that day or the session before.
- 21 Apr 2026+5.0%
Nothing announced by CELC that day or the session before.
Share of unusual movement by asset
For each asset, the share of CELC's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
Gedatolisib(Revtorpyk) | Approved | PI3K (class I isoforms) and mTORC1/mTORC2Small molecule | Breast Cancer HR+/HER2- Metastatic Breast Cancer |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
January 2028 (1)
What to watch
2029 (1)
March 2029 (1)
What to watch
Regulatory and conference events
(5)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $38M | $178M+ $465M short-term inv. | $73M-$66M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $31M | $182M+ $572M short-term inv. | $79M-$55M operating cash flow | report ↗ |
| 2026-Q1 | — | $33M | $145M+ $242M short-term inv. | $53M-$55M operating cash flow | report ↗ |
| 2025-Q3 | — | $35M | $74M+ $381M short-term inv. | $44M-$45M operating cash flow | report ↗ |
| 2025-Q2 | — | $40M | $46M+ $122M short-term inv. | $45M-$36M operating cash flow | report ↗ |
| 2025-Q1 | — | $32M | $16M+ $189M short-term inv. | $37M-$36M operating cash flow | report ↗ |
| 2024-Q3 | — | $28M | $13M+ $251M short-term inv. | $30M-$21M operating cash flow | report ↗ |
| 2024-Q2 | — | $23M | $30M+ $253M short-term inv. | $24M-$18M operating cash flow | report ↗ |
| 2024-Q1 | — | $21M | $31M+ $146M short-term inv. | $22M-$17M operating cash flow | report ↗ |
| 2023-Q3 | — | $17M | $26M+ $108M short-term inv. | $18M-$13M operating cash flow | report ↗ |
| 2023-Q2 | — | $14M | $32M+ $114M short-term inv. | $15M-$9.7M operating cash flow | report ↗ |
| 2023-Q1 | — | $11M | $34M+ $124M short-term inv. | $12M-$13M operating cash flow | report ↗ |
| 2022-Q3 | — | $9.6M | $57M | $11M-$9.3M operating cash flow | report ↗ |
| 2022-Q2 | — | $8.4M | $67M | $10.0M-$11M operating cash flow | report ↗ |
| 2022-Q1 | — | $6.7M | $78M | $7.9M-$5.9M operating cash flow | report ↗ |
| 2021-Q3 | — | $5.0M | $90M | $6.0M-$4.0M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $145M | $166M+ $276M short-term inv. | $44M-$153M operating cash flow | report ↗ |
Celcuity did not disclose revenue for 2025. R&D expense was $145M, up 39.2% YoY from $104.2M, while cash and cash equivalents stood at $165.7M and total cash, cash equivalents, and short-term investments were $441.5M at year-end. The company reported a full-year net loss of $177.0M, or $3.79 per share, compared with a net loss of $111.8M in 2024, and net cash used in operating activities was $153.3M for the full year.
The FDA accepted Celcuity’s New Drug Application for gedatolisib in HR+/HER2-/PIK3CA wild-type advanced breast cancer and granted Priority Review with a PDUFA goal date of July 17, 2026. Topline results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 study are expected in the second quarter of 2026, and results from the PIK3CA wild-type cohort were published in the Journal of Clinical Oncology. Management expects existing cash to finance operations through 2027 and remains on track for a potential commercial launch of gedatolisib in the third quarter of 2026, if approved.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $104M | $23M+ $213M short-term inv. | $28M-$83M operating cash flow | report ↗ |
| 2023-FY | — | $61M | $31M+ $150M short-term inv. | $16M-$54M operating cash flow | report ↗ |
| 2022-FY | — | $35M | $25M+ $144M short-term inv. | $10M-$36M operating cash flow | report ↗ |
| 2021-FY | — | $26M | $84M | $7.4M-$20M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 16 sales ($327.2M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-07 | Furcht Leo · director | Option exercise | 250 | $7.60 | $2K | Form 4 |
| 2026-10-07 | Furcht Leo · director | Option exercise (derivative) | 250 | — | — | Form 4 |
| 2026-10-01 | GRYSKA DAVID W · director | Award / grant | 893 | — | — | Form 4 |
| 2026-08-14 | Hahne Vicky · Chief Financial Officer | Award / grant | 16,000 | — | — | Form 4 |
| 2026-08-14 | Sullivan Brian F. · director, Chief Executive Officer | Award / grant | 80,000 | — | — | Form 4 |
| 2026-08-14 | Laing Lance G. · director, Chief Science Officer | Award / grant | 20,000 | — | — | Form 4 |
| 2026-08-14 | Hahne Vicky · Chief Financial Officer | Award / grant (derivative) | 10,000 | — | — | Form 4 |
| 2026-08-14 | Sullivan Brian F. · director, Chief Executive Officer | Award / grant (derivative) | 120,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 274 reporting institutions held 49.1M shares ($5.4B, 99.9% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BAKER BROS. ADVISORS LP | 7,915,792 | $903.5M |
| 2 | Avoro Capital Advisors LLC | 3,375,000 | $385.2M |
| 3 | PERCEPTIVE ADVISORS LLC | 3,127,200 | $356.9M |
| 4 | RTW INVESTMENTS, LP | 3,039,621 | $346.9M |
| 5 | BlackRock, Inc. | 2,711,532 | $309.5M |
| 6 | NEA Management Company, LLC | 2,285,561 | $260.9M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 1,782,894 | $203.5M |
| 8 | DEERFIELD MANAGEMENT COMPANY, L.P. | 1,714,000 | $195.6M |
| 9 | STATE STREET CORP | 1,518,705 | $173.3M |
| 10 | MORGAN STANLEY | 1,345,715 | $153.6M |
| 11 | Soleus Capital Management, L.P. | 1,284,378 | $146.6M |
| 12 | TANG CAPITAL MANAGEMENT LLC | 1,050,000 | $119.8M |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 891,070 | $101.7M |
| 14 | TORONTO DOMINION BANK | 882,758 | $100.8M |
| 15 | GOLDMAN SACHS GROUP INC | 764,975 | $87.3M |